Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, has announced it will host a corporate update webinar on September 2, 2026, at 4 p.m. EDT. The webinar will be followed by a live question-and-answer session. Founder, President and CEO Maria Maccecchini, Ph.D., will discuss recent progress, ongoing clinical programs and upcoming milestones, including the fully enrolled pivotal Phase 3 Alzheimer's disease (AD) trial, with top-line data and regulatory submissions expected in 2027.
The company also plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data. Its Parkinson's disease (PD) open-label study is already underway, and discussions are continuing regarding the initiation of a Parkinson's disease dementia program. These developments highlight Annovis's commitment to advancing its lead drug candidate, buntanetap, which is designed to address the underlying causes of neurodegeneration.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By targeting these proteins, Annovis aims to halt disease progression and improve cognitive and motor functions in patients suffering from Alzheimer's and Parkinson's diseases.
The announcement of the webinar and the upcoming milestones is significant for investors and patients alike. For investors, the progress of the Phase 3 AD trial is a key value driver, as positive results could lead to regulatory submissions and potential commercialization. For patients and the medical community, the development of a therapy that addresses multiple neurotoxic proteins could offer a new approach to treating these debilitating conditions, which currently have limited treatment options.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is focused on developing treatments for neurodegenerative diseases. The company's lead drug candidate, buntanetap, is being studied in clinical trials for both Alzheimer's and Parkinson's diseases. The company's mission is to improve the lives of patients by providing a therapy that targets the root causes of these diseases.
The webinar will provide an opportunity for stakeholders to gain insights into the company's progress and future plans. More information about the webinar and the company's news can be found in the company's newsroom at https://ibn.fm/ANVS. Additionally, for more information about Annovis Bio, visit www.annovisbio.com.
